title: Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.
abstract: The purine analogs, fludarabine nucleoside (FdA), and cladribine (CdA) (1 μM, 24 hours), significantly changed the levels of some surface antigens on the human B-cell lines MEC2 and Raji. Changes in the surface proteins were identified using a Cluster of Differentiation (CD) antibody microarray that captures live cells and confirmed by flow cytometry. For Raji cells, CdA up-regulated CD10, CD54, CD80, and CD86, with repression of CD22, while FdA up-regulated CD20, CD54, CD80, CD86 and CD95. For MEC2 cells, CdA up-regulated CD11a, CD20, CD43, CD45, CD52, CD54, CD62L, CD80, CD86, and CD95, but FdA had no effect. Up-regulation of particular CD antigens induced on a B-cell lymphoproliferative disorder by a purine analog could provide targets for therapeutic antibodies with synergistic cell killing.
authors.affiliation: School of Molecular and Microbial Biosciences, University of Sydney, Sydney, NSW 2006, Australia.
authors.forename: Carlos
authors.initials: C
authors.lastname: Cassano
authors.forename: Swetlana
authors.initials: S
authors.lastname: Mactier
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Mulligan
authors.forename: Larissa
authors.initials: L
authors.lastname: Belov
authors.forename: Pauline
authors.initials: P
authors.lastname: Huang
authors.forename: Richard I
authors.initials: RI
authors.lastname: Christopherson
references.citation: Leuk Res. 2004 May;28(5):429-42
references.pmid: 15068894
references.citation: Clin Cancer Res. 2003 Aug 1;9(8):3204-12
references.pmid: 12912974
references.citation: Blood. 2002 Mar 15;99(6):2245-7
references.pmid: 11877305
references.citation: Tissue Antigens. 2004 Jan;63(1):46-53
references.pmid: 14651523
references.citation: Leuk Lymphoma. 2004 Feb;45(2):205-19
references.pmid: 15101704
references.citation: Leuk Lymphoma. 2004 May;45(5):937-44
references.pmid: 15291352
references.citation: Leuk Lymphoma. 2001 Jun;42(1-2):5-12
references.pmid: 11699221
references.citation: Transfus Apher Sci. 2005 Feb;32(1):33-44
references.pmid: 15737872
references.citation: Br J Haematol. 2006 Oct;135(2):184-97
references.pmid: 16939496
references.citation: Cancer. 2006 Dec 15;107(12):2817-25
references.pmid: 17120198
references.citation: J Clin Pathol. 1998 May;51(5):364-9
references.pmid: 9708202
references.citation: Haematologica. 2003 Aug;88(8):864-73
references.pmid: 12935974
references.citation: Biochem J. 2001 Nov 1;359(Pt 3):537-46
references.pmid: 11672427
references.citation: N Engl J Med. 1995 Oct 19;333(16):1052-7
references.pmid: 7675049
references.citation: Blood. 2004 Oct 15;104(8):2475-83
references.pmid: 15217838
references.citation: J Clin Oncol. 2005 Jul 1;23(19):4390-8
references.pmid: 15994148
references.citation: Clin Cancer Res. 2006 Jul 1;12(13):4027-35
references.pmid: 16818702
references.citation: J Biol Chem. 1996 Nov 1;271(44):27686-95
references.pmid: 8910360
references.citation: Blood. 2005 Jan 1;105(1):49-53
references.pmid: 15138165
references.citation: Blood. 1999 Nov 1;94(9):3067-76
references.pmid: 10556191
references.citation: J Immunol. 2006 Sep 1;177(5):3063-73
references.pmid: 16920943
references.citation: Blood Rev. 2004 Jun;18(2):137-48
references.pmid: 15010151
references.citation: J Biol Chem. 2002 Mar 8;277(10):7766-75
references.pmid: 11726649
references.citation: J Clin Oncol. 2006 Apr 1;24(10):1590-6
references.pmid: 16575010
references.citation: Immunology. 1998 Aug;94(4):580-6
references.pmid: 9767448
references.citation: Curr Drug Targets. 2006 Oct;7(10):1301-11
references.pmid: 17073592
references.citation: Oncogene. 2004 Apr 1;23(14):2523-30
references.pmid: 14676827
references.citation: Leuk Res. 1999 Feb;23(2):127-36
references.pmid: 10071128
references.citation: Leukemia. 1997 Apr;11(4):572-80
references.pmid: 9096698
references.citation: J Biol Chem. 2000 Oct 6;275(40):31460-8
references.pmid: 10908570
references.citation: Leuk Lymphoma. 2001 Feb;40(5-6):551-64
references.pmid: 11426528
references.citation: J Natl Cancer Inst. 1966 Oct;37(4):547-59
references.pmid: 4288580
references.citation: Br J Haematol. 2001 Sep;114(4):800-9
references.pmid: 11564066
references.citation: Cancer. 2006 Jun 1;106(11):2412-20
references.pmid: 16649223
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3991S-4S
references.pmid: 14506198
references.citation: Leukemia. 1999 Nov;13(11):1854-8
references.pmid: 10557062
references.citation: J Biol Chem. 2002 Mar 8;277(10):7955-61
references.pmid: 11773067
references.citation: Clin Immunol. 2004 Apr;111(1):28-37
references.pmid: 15093549
references.citation: Blood. 2002 Nov 1;100(9):3115-20
references.pmid: 12384407
references.citation: Ann Hematol. 1996 Aug;73(2):79-84
references.pmid: 8774616
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4079-88
references.pmid: 15767648
references.citation: Leuk Res. 2005 Oct;29(10):1141-51
references.pmid: 16111532
references.citation: Leuk Res. 2008 Feb;32(2):315-22
references.pmid: 17561254
references.citation: Int J Biochem Cell Biol. 1998 Jul;30(7):833-42
references.pmid: 9722988
references.citation: Leukemia. 2000 Feb;14(2):299-306
references.pmid: 10673748